STEVEN M. DUBINETT, M.D.
Osteopathic Medicine in Los Angeles, CA
License number
California G45998
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
10833 Chs, Los Angeles, CA 90095
Phone
(310) 267-2725
Personal information
See more information about STEVEN M. DUBINETT at radaris.comName
Address
Phone
Los Angeles, CA
1319 Harvard St, Santa Monica, CA 90404
2125 Roscomare Rd, Los Angeles, CA 90077
Professional information
See more information about STEVEN M. DUBINETT at trustoria.com
Steven M Dubinett, Los Angeles CA
Steven M Dubinett, Los Angeles CA
Specialties:
Pulmonologist
Address:
2125 Roscomare Rd, Los Angeles, CA 90077
10833 Le Conte Ave, Los Angeles, CA 90095
10833 Le Conte Ave, Los Angeles, CA 90095
Education:
University of Medicine and Dentistry of New Jersey, New Jersey Medical School - Doctor of Medicine
Massachusetts General Hospital - Fellowship - Pulmonary Disease (Internal Medicine)
Ronald Reagan UCLA Medical Center - Residency - Internal Medicine
Massachusetts General Hospital - Fellowship - Pulmonary Disease (Internal Medicine)
Ronald Reagan UCLA Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)
Steven Michael Dubinett, Los Angeles CA
Steven Michael Dubinett, Los Angeles CA
Specialties:
Internal Medicine, Pulmonary Disease
Work:
Va Greater Los Angeles Healthcare System
11301 Wilshire Blvd, Los Angeles, CA 90073 UCLA Medical Center
10833 Le Conte Ave, Los Angeles, CA 90095
11301 Wilshire Blvd, Los Angeles, CA 90073 UCLA Medical Center
10833 Le Conte Ave, Los Angeles, CA 90095
Education:
UMDNJ (1980), UCLA Medical Center (1984) *Internal Medicine, Massachusetts General Hospital (1988) *Pulmonary Disease
Protein Markers For Lung Cancer Detection And Methods Of Using Thereof
Protein Markers For Lung Cancer Detection And Methods Of Using Thereof
US Patent:
2012031, Dec 13, 2012
Filed:
Jan 7, 2011
Appl. No.:
13/520660
Inventors:
Steven M. Dubinett - Los Angeles CA, US
Brian K. Gardner - Los Angeles CA, US
David Elashoff - Los Angeles CA, US
Kostyantyn Krysan - Los Angeles CA, US
Brian K. Gardner - Los Angeles CA, US
David Elashoff - Los Angeles CA, US
Kostyantyn Krysan - Los Angeles CA, US
International Classification:
G01N 33/574, G06F 19/10, C12Q 1/68
US Classification:
435 612, 436501, 702 19
Abstract:
Disclosed herein are methods, devices and kits for detecting, diagnosing, or categorizing a subject as having lung cancer. As disclosed herein, at least three of the following protein biomarkers: VEGF, CGSF, MIG, RANTES, IL-2, IL-3 and MDC, are used to determine whether a subject at high-risk for lung cancer likely has lung cancer, such as stage I non-small cell lung cancer.
Dr. Steven M Dubinett, Los Angeles CA - MD (Doctor of Medicine)
Dr. Steven M Dubinett, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
VA Greater Las Angls Plm Crt Cr
11301 Wilshire Blvd, Los Angeles 90073
(310) 268-3021 (Phone)
11301 Wilshire Blvd, Los Angeles 90073
(310) 268-3021 (Phone)
Certifications:
Critical Care Medicine, 1991, Internal Medicine, 1983, Pulmonary Disease, 1988
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
VA Greater Las Angls Plm Crt Cr
11301 Wilshire Blvd, Los Angeles 90073
Cedars - Sinai Medical Center
8700 West Beverly Blvd, West Hollywood 90048
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
Olive View - UCLA Medical Center
14445 Olive View Dr, Sylmar 91342
11301 Wilshire Blvd, Los Angeles 90073
Cedars - Sinai Medical Center
8700 West Beverly Blvd, West Hollywood 90048
Ronald Reagan UCLA Medical Center
757 Westwood Plz, Los Angeles 90095
Olive View - UCLA Medical Center
14445 Olive View Dr, Sylmar 91342
Education:
Medical School
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1980
Umdnj-University Hospital
UCLA
Massachusetts General Hospital
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1980
Umdnj-University Hospital
UCLA
Massachusetts General Hospital
Methods Of Using Secondary Lymphoid Organ Chemokine To Modulate Physiological Processes In Mammals
Methods Of Using Secondary Lymphoid Organ Chemokine To Modulate Physiological Processes In Mammals
US Patent:
2004017, Sep 9, 2004
Filed:
Jan 13, 2004
Appl. No.:
10/756101
Inventors:
Steven Dubinett - Los Angeles CA, US
Robert Strieter - Sherman Oaks CA, US
Sherven Sharma - Culver City CA, US
Raj Batra - Beverly Hills CA, US
Robert Strieter - Sherman Oaks CA, US
Sherven Sharma - Culver City CA, US
Raj Batra - Beverly Hills CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
International Classification:
A61K038/19
US Classification:
424/085100, 424/093700
Abstract:
The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.
Vault Complexes For Cytokine Delivery
Vault Complexes For Cytokine Delivery
US Patent:
2012021, Aug 23, 2012
Filed:
Nov 2, 2010
Appl. No.:
13/505420
Inventors:
Leonard H. Rome - Los Angeles CA, US
Valerie A. Kickhoefer - Los Angeles CA, US
Steven M. Dubinett - Los Angeles CA, US
Sherven Sharma - Culver City CA, US
Upendra K. Kar - Dhenkanal, IN
Valerie A. Kickhoefer - Los Angeles CA, US
Steven M. Dubinett - Los Angeles CA, US
Sherven Sharma - Culver City CA, US
Upendra K. Kar - Dhenkanal, IN
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 39/00, C07H 21/04, C12N 15/63, C12N 5/00, C12N 5/02, A61P 35/00, A61K 38/00, C12N 9/96, A61K 38/54, C07K 14/52, A61P 37/02, C07K 14/00, C12N 5/071
US Classification:
4241851, 530350, 536 234, 536 231, 4353201, 435325, 435375, 435366, 4353723, 4241841, 514 193, 435188, 424 943, 530395
Abstract:
The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.
Methods Of Using Secondary Lymphoid Organ Chemokine To Modulate Physiological Processes In Mammals
Methods Of Using Secondary Lymphoid Organ Chemokine To Modulate Physiological Processes In Mammals
US Patent:
2003017, Sep 18, 2003
Filed:
Apr 18, 2002
Appl. No.:
10/124862
Inventors:
Steven Dubinett - Los Angeles CA, US
Robert Strieter - Sherman Oaks CA, US
Sherven Sharma - Culver City CA, US
Raj Batra - Beverly Hills CA, US
Robert Strieter - Sherman Oaks CA, US
Sherven Sharma - Culver City CA, US
Raj Batra - Beverly Hills CA, US
International Classification:
G01N033/53
US Classification:
435/007100
Abstract:
The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.